This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

Online Registration Closes June 10

  • 00
  • 00
  • 00
  • 00
June 14-16, 2022
Delivered as a Hybrid EventIntercontinental Mark Hopkins Hotel, San Francisco, California

Tina Albertson
CMO and Head of Development at Lyell Immunopharma, USA


Tina Albertson, M.D., Ph.D., has spent her career advancing innovative oncology therapies. She has served as Lyell’s Chief Medical Officer and Head of Development since July 2020. Prior to joining Lyell, Dr. Albertson was Vice President of Global Drug Development responsible for the development and registration strategy for Breyanzi® (lisocabtagene maraleucel), at Juno Therapeutics, a BMS company. Dr. Albertson is a pediatric oncologist who trained at Seattle Children’s Hospital and the FHCRC. Dr. Albertson earned a Ph.D. in Cancer Biology from University of Washington, an M.D. from Stanford University, and a B.S. in Molecular Biology from University of Oregon.

Agenda Sessions

  • Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours